EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Leveraging Organ‐on‐Chip Models to Investigate Host–Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease

Tim Kaden, Raquel Alonso-Román, Johannes Stallhofer, Mark S Gresnigt, Bernhard Hube, Alexander S Mosig iD

Advanced Healthcare Materials · 2025

DOI: 10.1002/adhm.202402756 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Tim Kaden und 5 weiteren Autor:innen. Beteiligte Einrichtung: Dynamic42 GmbH, 07745, Jena, Germany. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Lab-On-A-Chip Devices, Gastrointestinal Microbiome, Models, Biological. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 315 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Germany's Excellence Strategy-EXC 2051, Carl Zeiss Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inflammatory bowel disease (IBD) is an idiopathic gastrointestinal disease with drastically increasing incidence rates. Due to its multifactorial etiology, a precise investigation of the pathogenesis is extremely difficult. Although reductionist cell culture models and more complex disease models in animals have clarified the understanding of individual disease mechanisms and contributing factors of IBD in the past, it remains challenging to bridge research and clinical practice. Conventional 2D cell culture models cannot replicate complex host–microbiota interactions and stable long‐term microbial culture. Further, extrapolating data from animal models to patients remains challenging due to genetic and environmental diversity leading to differences in immune responses. Human intestine organ‐on‐chip (OoC) models have emerged as an alternative in vitro model approach to investigate IBD. OoC models not only recapitulate the human intestinal microenvironment more accurately than 2D cultures yet may also be advantageous for the identification of important disease‐driving factors and pharmacological interventions targets due to the possibility of emulating different complexities. The predispositions and biological hallmarks of IBD focusing on host–microbiota interactions at the intestinal mucosal barrier are elucidated here. Additionally, the potential of OoCs to explore microbiota‐related therapies and personalized medicine for IBD treatment is discussed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Inflammatory Bowel DiseasesLab-On-A-Chip DevicesGastrointestinal MicrobiomeModels, BiologicalHumansIntestinal MucosaAnimals

Stichwörter der Autor:innen

IBD treatmenthost–microbiota interactionsinflammatory bowel diseaseintestine‐on‐chip

Autor:innen und Institutionen

  • Dynamic42 GmbH, 07745, Jena, Germany.
  • Institute of Biochemistry II, Center for Sepsis Control and Care, Jena University Hospital, 07747, Jena, Germany.
  • Department of Microbial Pathogenicity Mechanisms, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knöll-Institute, 07745, Jena, Germany.
  • Cluster of Excellence Balance of the Microverse, Friedrich Schiller University Jena, 07745, Jena, Germany.
  • Junior Research Group Adaptive Pathogenicity Strategies, Leibniz Institute for Natural Product Research and Infection Biology - Hans-Knöll-Institute, 07745, Jena, Germany.
  • Department of Internal Medicine IV, Jena University Hospital, 07747, Jena, Germany.

ORCID-Profile: Alexander S Mosig

Förderung

  • Deutsche Forschungsgemeinschaft
  • Germany's Excellence Strategy-EXC 2051
  • Carl Zeiss Foundation
  • Thüringer Aufbaubank
  • DFG Emmy Noether Program
  • DFG Collaborative Research Centre (CRC)/Transregio (TRR)
  • DFG Priority Program
  • Exit strategies of intracellular pathogens

Zitieren

APA

Kaden, T., Alonso-Román, R., Stallhofer, J., Gresnigt, M. S., Hube, B., & Mosig, A. S. (2025). Leveraging Organ‐on‐Chip Models to Investigate Host–Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202402756

Vancouver

Kaden T, Alonso-Román R, Stallhofer J, Gresnigt MS, Hube B, Mosig AS. Leveraging Organ‐on‐Chip Models to Investigate Host–Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202402756

BibTeX
@article{Kaden2025,
  author = {Kaden, Tim and Alonso-Román, Raquel and Stallhofer, Johannes and Gresnigt, Mark S and Hube, Bernhard and Mosig, Alexander S},
  title = {Leveraging Organ‐on‐Chip Models to Investigate Host–Microbiota Dynamics and Targeted Therapies for Inflammatory Bowel Disease},
  journal = {Advanced Healthcare Materials},
  year = {2025},
  doi = {10.1002/adhm.202402756}
}
Kostenlos starten →